MyAverix Finance MyAverix Finance

VI · Healthcare

Marinomed Biotech AG (MARI)

Biotechnology

Marinomed Biotech AG (MARI) is listed on VI in the Healthcare sector. Industry: Biotechnology. As of 2026-03-22, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-03-22

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for MARI

P/E ratio
18.00

Marinomed Biotech AG (MARI) — FAQ

What is MARI's P/E ratio?

The price-to-earnings (P/E) ratio for Marinomed Biotech AG (MARI) is 18.00 (data as of 2026-03-22).

Does Marinomed Biotech AG pay a dividend?

Dividend yield is not available in the current snapshot for Marinomed Biotech AG (MARI). Check the MyAverix Finance app for the latest dividend data.

What sector is Marinomed Biotech AG in?

Marinomed Biotech AG (MARI) is classified in the Healthcare sector (Biotechnology industry).

What exchange is MARI listed on?

MARI is listed on VI.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play